<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26003" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>NPH Insulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saleem</surname>
            <given-names>Fatima</given-names>
          </name>
          <aff>King Edward Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fatima Saleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26003.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">NPH (neutral protamine Hagedorn) insulin is a medication used to treat and manage diabetes mellitus, which is a significant risk factor for coronary artery disease. Most cases are not attributable to any specific etiology. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of NPH insulin therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with diabetes mellitus and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of NPH insulin.</p></list-item><list-item><p>Summarize the adverse effects and contraindications of NPH insulin.</p></list-item><list-item><p>Describe appropriate monitoring and toxicity of NPH insulin.</p></list-item><list-item><p>Outline and explain interprofessional team strategies for improving care coordination and communication to advance NPH insulin and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26003&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26003">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26003.s2" sec-type="Indications">
        <title>Indications</title>
        <p>NPH (Neutral Protamine Hagedorn) insulin is an insoluble intermediate-acting insulin preparation first created in 1946. The name refers to<bold> N</bold> for neutral, <bold>P</bold> for protamine (a protein), and <bold>H</bold> for its creator scientist name Hans Christian Hagedorn. It is on the list of essential medicines of the World Health Organization (WHO). NPH insulin is FDA-approved in the adult and pediatric population to control type 1 and type 2 diabetes mellitus. It is currently the most widely used basal insulin that simulates the physiological basal insulin action. Basal insulin provides a constant supply of insulin in the body necessary for glucose regulation despite fasting, such as between meals and overnight. NPH insulin offers a sustained release of insulin over an extended period.<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r2">[2]</xref><xref ref-type="bibr" rid="article-26003.r3">[3]</xref><xref ref-type="bibr" rid="article-26003.r4">[4]</xref>&#x000a0;It is also useful in gestational diabetes. Pregnancy may require higher doses of insulin.</p>
        <p>American Diabetes Association guidelines recommend an NPH insulin dose of 0.4 to 1.0 units/kg/day subcutaneously to manage type 1 diabetes mellitus. A higher dose is necessary during medical illness and puberty. A dose of 0.1&#x000a0;to 0.2 units/kg/day subcutaneously is recommended in type 2 diabetes mellitus depending on body weight and the patient&#x02019;s hyperglycemia. The treatment is individualized, and the NPH insulin dose is titrated accordingly over days to weeks.<xref ref-type="bibr" rid="article-26003.r5">[5]</xref></p>
      </sec>
      <sec id="article-26003.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>NPH insulin is an isophane suspension of human insulin and is categorized as an intermediate-acting insulin. It helps increase the cellular intake of glucose in the liver, adipose tissue, and skeletal muscles. It acts as basal insulin and stimulates the liver to promote hepatic glycogen synthesis, fatty acid metabolism for lipoprotein synthesis. In skeletal muscles, it promotes glycogen and protein synthesis. In adipose tissue, it helps in triglyceride synthesis and regulates lipolysis by inhibiting triglyceride hydrolysis. At the cellular level, it makes the cell membrane permeable for ions such as potassium, magnesium, and phosphorus and increases their cellular uptake. &#x000a0;</p>
        <p>The intermediate-acting NPH insulin is obtained from the precipitation of recombinant synthesized human insulin with zinc in the presence of protamine, a basic polyarginine peptide. This process occurs at a neutral pH in an insulin and protamine ratio of 5: 1. This formulation method gives NPH the property of protraction, i.e., slow release of insulin from the precipitated insulin present at the injection site after subcutaneous injection.<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r2">[2]</xref><xref ref-type="bibr" rid="article-26003.r3">[3]</xref><xref ref-type="bibr" rid="article-26003.r4">[4]</xref><xref ref-type="bibr" rid="article-26003.r5">[5]</xref>&#x000a0;After injecting the protein-insulin complex, the solvent from NPH insulin suspension diffuses into the subcutaneous tissue. These insulin crystals are stacked up like a heap at the injection depot and dissolve gradually, leading to the protracted action of NPH.</p>
        <p>Later protamine-splitting enzymes and macrophages invade the subcutaneous tissue and dissolve the NPH insulin suspension heaps, thus releasing insulin. These varied heaps are also thought to be the cause of variability present in the pharmacodynamics and pharmacokinetics of NPH insulin. The exact mechanism of binding of preformed insulin-protamine aggregate and NPH insulin dissociation at tissue level is unknown.<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r3">[3]</xref><xref ref-type="bibr" rid="article-26003.r5">[5]</xref></p>
        <p>
<bold>Pharmacodynamics and Pharmacokinetics </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The onset of action - 1&#x000a0;to 3 hours</p>
          </list-item>
          <list-item>
            <p>Time to Peak effect - 4&#x000a0;to 8 hours</p>
          </list-item>
          <list-item>
            <p>Time to reach peak effect in plasma &#x02013; 6&#x000a0;to 10 hours</p>
          </list-item>
          <list-item>
            <p>Total duration - 14&#x000a0;to 24 hours&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Distribution &#x02013; Fast distribution in extracellular fluid</p>
          </list-item>
          <list-item>
            <p>Metabolism &#x02013; Mainly liver. Some metabolism in kidney and muscle.</p>
          </list-item>
          <list-item>
            <p>Excretion &#x02013; Urine metabolites</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26003.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Crystalline NPH insulin administration is subcutaneous, not intramuscular or intravenous. NPH&#x000a0;insulin is available in a two-phase solution, which means that apart from NPH, it has a solvent or a rapid-acting&#x000a0;insulin solution. It comes in the form of a subcutaneous suspension or suspension pen-injector. Refer to the label of a specific product for more details regarding formulations and dose concentrations. &#x000a0;</p>
        <p>The abdominal subcutaneous injection causes quicker absorption as compared to arms or thighs. The most significant advantage of NPH is that it can be included in premixed formulation with regular insulin. NPH in premixed formulations does not affect the potency and time-action profile of regular insulin. Exercise, massage, and local heat application increase NPH insulin absorption.<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r4">[4]</xref><xref ref-type="bibr" rid="article-26003.r6">[6]</xref></p>
        <p>NPH insulin pen requires adequate mixing to get complete resuspension before injecting it. It may be given once or twice daily.<xref ref-type="bibr" rid="article-26003.r7">[7]</xref><xref ref-type="bibr" rid="article-26003.r8">[8]</xref>&#x000a0;Since the action profile of NPH insulin does not cover 24 hours, a twice-daily dose in the morning and evening or bedtime is the recommended regimen, which applies to the premixed formulations as well. Premixed formulations contain 70&#x000a0;to 75% of NPH insulin. The American Diabetes Association recommends moving to premixed formulations in well-controlled diabetes mellitus when HbA1c remains above target, the basal insulin is well titrated, or if the dose exceeds 0.5 units/kg/day.<xref ref-type="bibr" rid="article-26003.r9">[9]</xref><xref ref-type="bibr" rid="article-26003.r6">[6]</xref></p>
      </sec>
      <sec id="article-26003.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>NPH insulin has a somewhat higher risk of hypoglycemia. Inadequate resuspension is thought to contribute to the high day-to-day variability in the pharmacodynamic and pharmacokinetic profile of NPH insulin, leading to hypoglycemia. Patients can adequately resuspend NPH by rotating the vial several times until it is uniformly cloudy<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r5">[5]</xref><xref ref-type="bibr" rid="article-26003.r3">[3]</xref><xref ref-type="bibr" rid="article-26003.r6">[6]</xref></p>
        <p>It is often difficult to obtain the target glycosylated hemoglobin A1c due to its variable absorption and rapid peak.<xref ref-type="bibr" rid="article-26003.r10">[10]</xref>&#x000a0;Also, breakfast injection may not&#x000a0;provide coverage till the evening dose, and likewise, the evening dose may not meet the insulin requirement until morning.</p>
        <p>Nocturnal hypoglycemia: The patient is given NPH insulin in the evening. NPH Insulin peak occurs at midnight when the body does not require as much insulin and may cause nocturnal hypoglycemia.</p>
        <p>Fasting hyperglycemia: Morning blood glucose can be high in patients who take NPH insulin in the evening. The duration of insulin action is not&#x000a0;for its effect to last until the morning,&#x000a0;potentially leading to fasting hyperglycemia, managed by giving NPH insulin at bedtime rather than with the evening meal. Fasting hyperglycemia can also occur with the dawn phenomenon, where insulin resistance and higher insulin need occurs after 5:00&#x000a0;AM.<xref ref-type="bibr" rid="article-26003.r4">[4]</xref></p>
        <p>NPH insulin can cause weight gain.<xref ref-type="bibr" rid="article-26003.r11">[11]</xref>&#x000a0;Other side effects include peripheral&#x000a0;edema, hypokalemia, and lipodystrophy, which may manifest as skin atrophy or hypertrophy.</p>
        <p>Hypersensitivity reaction to insulin usually includes a local injection site reaction such as swelling or redness, but rarely life-threatening anaphylaxis can also occur.<xref ref-type="bibr" rid="article-26003.r12">[12]</xref><xref ref-type="bibr" rid="article-26003.r13">[13]</xref></p>
      </sec>
      <sec id="article-26003.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>NPH insulin is contraindicated in hypersensitivity reactions. Patients may become hypersensitive to insulin formulation or any of the drug products. Allergic reactions to various allergens or additives such as zinc, protamine, and metal-cresol can occur. The patient may have pruritis, followed by erythema and rash all over the body.<xref ref-type="bibr" rid="article-26003.r14">[14]</xref>&#x000a0;NPH insulin is also contraindicated in patients who have repeated episodes of severe hypoglycemia. Hypoglycemia can be life-threatening.</p>
      </sec>
      <sec id="article-26003.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>NPH cannot classify as ideal basal insulin. It shows much variability in its absorption and action after subcutaneous injection.<xref ref-type="bibr" rid="article-26003.r1">[1]</xref><xref ref-type="bibr" rid="article-26003.r3">[3]</xref>&#x000a0;This situation leads to fluctuations in blood glucose control and causes hypoglycemic episodes. For this reason, it requires meticulous monitoring, including fasting blood glucose and changes in HbA1c values.<xref ref-type="bibr" rid="article-26003.r7">[7]</xref><xref ref-type="bibr" rid="article-26003.r11">[11]</xref>&#x000a0;NPH insulin requires electrolyte monitoring due to the risk of hypokalemia. In addition to consistent glucose monitoring, it requires monitoring&#x000a0;the patient's physical activity because it may change the insulin requirement. Likewise, diet patterns require vigilance.</p>
        <p>Frequent glucose monitoring is required in children on NPH insulin because of the greatly varying dose need and marked changes in insulin requirements during the growth period of children.<xref ref-type="bibr" rid="article-26003.r6">[6]</xref></p>
      </sec>
      <sec id="article-26003.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>NPH insulin toxicity can lead to severe hypoglycemia, which can cause seizures and even irreversible neurological deficits. It may be life-threatening or also cause death. Patients with renal or hepatic impairment are at higher risk of having hypoglycemia. Iatrogenic hypoglycemia can occur in medical facilities. Mild/moderate hypoglycemia is manageable by taking sugar-containing food or drinks. Diabetes mellitus patients and those on NPH insulin should have a source of sugar with them. Severe hypoglycemia and unconscious patients require hospitalization. Patients require treatment with an injection of glucagon or intravenous administration of glucose.</p>
      </sec>
      <sec id="article-26003.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>For a patient to achieve successful treatment with NPH insulin, an interprofessional team effort is necessary. Patient education is imperative to improve outcomes from NPH insulin treatment. Healthcare workers should teach patients how to resuspend NPH premixed insulin before injection. Health care professionals, particularly the diabetes nurse educator, should demonstrate the correct injection technique and educate patients&#x000a0;about the importance of timing and accuracy of dosage. Regular monitoring is vital to avoid adverse effects. Patients need a detailed explanation of the side effects of insulin, and if available, a dedicated diabetic education session by a certified diabetic educator is necessary; this can be a nurse or pharmacist, preferably with specialty training in diabetes management. This interprofessional approach will drive improved patient compliance and outcomes with fewer adverse effects. [Level 5]</p>
        <p>Patients may reduce insulin dose or miss it altogether, either because of the fear of hypoglycemia or the high cost of insulin. The high price is also a barrier to compliance. Some patients may find inflexible dose timing problematic due to social factors and work schedules. NPH insulin time-specific dosing schedule may require a lifestyle change, which may impact adherence to therapy. An interprofessional approach should be adopted, including a dietician, nurses, and primary care physician to improve outcomes. An endocrinology specialist should be involved in caring for patients with difficult to control diabetes mellitus or patients with labile blood glucose. An interprofessional approach, including clinicians, nurses, pharmacists, and dieticians, can improve the odds of successful glucose control with NPH insulin. [Level 5]</p>
        <p>Recent clinical trials have shown that modern basal insulin analogs such as insulin glargine and insulin detemir have a lower risk of hypoglycemia and lower variability of fasting blood glucose compared to NPH insulin. But in clinical practice, these new analogs may not have better outcomes regarding the quality of life, morbidity, or cost.<xref ref-type="bibr" rid="article-26003.r10">[10]</xref><xref ref-type="bibr" rid="article-26003.r2">[2]</xref><xref ref-type="bibr" rid="article-26003.r6">[6]</xref></p>
      </sec>
      <sec id="article-26003.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26003&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26003">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26003/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26003">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26003.s11">
        <title>References</title>
        <ref id="article-26003.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucidi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Porcellati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marinelli Andreoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carriero</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Candeloro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolli</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Fanelli</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>2204</fpage>
            <page-range>2204-10</page-range>
            <pub-id pub-id-type="pmid">26358287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinemann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Linkeschova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rave</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hompesch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sedlak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.</article-title>
            <source>Diabetes Care</source>
            <year>2000</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>644</fpage>
            <page-range>644-9</page-range>
            <pub-id pub-id-type="pmid">10834424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gangopadhyay</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Modern basal insulin analogs: An incomplete story.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>784</fpage>
            <page-range>784-93</page-range>
            <pub-id pub-id-type="pmid">25364672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirsch</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Type 1 diabetes mellitus and the use of flexible insulin regimens.</article-title>
            <source>Am Fam Physician</source>
            <year>1999</year>
            <month>Nov</month>
            <day>15</day>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>2343</fpage>
            <page-range>2343-52, 2355-6</page-range>
            <pub-id pub-id-type="pmid">10593324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">27593206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgraf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sandow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy.</article-title>
            <source>Eur Endocrinol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-17</page-range>
            <pub-id pub-id-type="pmid">29632581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pampanelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fanelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porcellati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bartocci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Vincenzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cordoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brunetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolli</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.</article-title>
            <source>Diabetes</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>12</issue>
            <fpage>2142</fpage>
            <page-range>2142-8</page-range>
            <pub-id pub-id-type="pmid">11118018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Vu</surname>
                <given-names>TTH</given-names>
              </name>
              <name>
                <surname>Isip-Tan</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Mudjanarko</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Bajpai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mabunay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bunnag</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>521</fpage>
            <page-range>521-532</page-range>
            <pub-id pub-id-type="pmid">29276400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: <italic>Standards of Medical Care in Diabetes-2019</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>Suppl 1</issue>
            <fpage>S90</fpage>
            <page-range>S90-S102</page-range>
            <pub-id pub-id-type="pmid">30559235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horvath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jeitler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berghold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ebrahim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Gratzer</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Plank</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pieber</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Siebenhofer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Apr</month>
            <day>18</day>
            <issue>2</issue>
            <fpage>CD005613</fpage>
            <pub-id pub-id-type="pmid">17443605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fournier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Germe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Theobald</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Lehmacher</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.</article-title>
            <source>Ger Med Sci</source>
            <year>2014</year>
            <volume>12</volume>
            <fpage>Doc14</fpage>
            <pub-id pub-id-type="pmid">25332702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quiralte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>de Pablos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carrillo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.</article-title>
            <source>Allergy</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>421</fpage>
            <page-range>421-4</page-range>
            <pub-id pub-id-type="pmid">8837667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YQ</given-names>
              </name>
            </person-group>
            <article-title>Allergic shock and death associated with protamine administration in a diabetic patient.</article-title>
            <source>Clin Ther</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>1729</fpage>
            <page-range>1729-32</page-range>
            <pub-id pub-id-type="pmid">21194595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26003.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belhekar</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tayade</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalwadi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Munshi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Varthakavi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>227</fpage>
            <page-range>227-9</page-range>
            <pub-id pub-id-type="pmid">25878390</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
